Retatrutide discontinuation data is limited because the compound is still in clinical trials and long-term follow-up after cessation has not been extensively studied
In the context of AD, the focus should be on individuals at risk, such as those with MCI, subjective cognitive decline, elders with positive A or tau biomarkers, APOE -4-carriers or healthy elderly individuals with high-risk scores [105]
doi: 10.1056/NEJMoa1612917 16 GreenJBHernandezAFDAgostinoRBGrangerCBJanmohamedSJonesNPet al
Expanded Approval for Pediatrics With rising rates of diabetes and excess weight in children, the FDA has expanded the use of incretin-based therapies to younger populations
Conclusion Staying motivated during GLP-1 treatment hinges on setting clear, personal goals that adapt as you progress, tackling challenges like side effects or plateaus before they throw you off track, and building routines that fit your lifestyle
Hormone and Metabolic Research , 36(1112), 735741
